The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial
暂无分享,去创建一个
M. Picchioni | M. Crawford | T. Barnes | V. Leeson | C. Paton | B. Barrett | N. Husain | Z. Hoare | R. Sanatinia | G. Lamph | P. Sen | S. Gibbon | R. Evans | F. Larkin | Aisling McQuaid | Jack Cheshire | K. Anagnostakis | Louise Millard | I. Qurashi | Paul Moran | A. McQuaid | Paul A. Moran | P. Moran
[1] C. Plymen,et al. Clozapine and cardiotoxicity – A guide for psychiatrists written by cardiologists , 2019, Psychiatry Research.
[2] A. McNulty,et al. Improved mental health among LABILE study participants: A qualitative exploration. , 2019, Personality and mental health.
[3] C. Correll,et al. Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study. , 2018, Journal of personality disorders.
[4] M. Picchioni,et al. Experiences of women in secure care who have been prescribed clozapine for borderline personality disorder , 2016, Borderline Personality Disorder and Emotion Dysregulation.
[5] Vladimir Carli,et al. Suicide prevention strategies revisited: 10-year systematic review. , 2016, The lancet. Psychiatry.
[6] M. Brüne,et al. Borderline Personality Disorder , 2016, Evolution, medicine, and public health.
[7] M. Crawford,et al. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. , 2015, The Journal of clinical psychiatry.
[8] J. Boydell,et al. Clozapine in borderline personality disorder: a review of the evidence. , 2014, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[9] R. Borschmann,et al. Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial , 2013, British Journal of Psychiatry.
[10] M. Picchioni,et al. A case series of clozapine for borderline personality disorder. , 2013, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[11] C. Long,et al. Engagement in psychosocial treatment: its relationship to outcome and care pathway progress for women in medium-secure settings. , 2012, Criminal behaviour and mental health : CBMH.
[12] G. Rücker,et al. Psychological therapies for people with borderline personality disorder. , 2012, The Cochrane database of systematic reviews.
[13] M. Crawford,et al. Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting , 2011, Acta psychiatrica Scandinavica.
[14] A. Vita,et al. Antipsychotics, Antidepressants, Anticonvulsants, and Placebo on the Symptom Dimensions of Borderline Personality Disorder: A Meta-Analysis of Randomized Controlled and Open-Label Trials , 2011, Journal of clinical psychopharmacology.
[15] L. Hall,et al. Women referred for medium secure inpatient care: a population study over a six-year period , 2011 .
[16] D Russell,et al. Generalized method for adaptive randomization in clinical trials , 2011, Statistics in medicine.
[17] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[18] S. Schulz,et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. , 2011, The Journal of clinical psychiatry.
[19] E. Overton,et al. Non-completion of personality disorder treatments: a systematic review of correlates, consequences, and interventions. , 2010, Clinical psychology review.
[20] P. Fonagy,et al. Engagement and retention in specialist services for people with personality disorder , 2009, Acta psychiatrica Scandinavica.
[21] J. Mullan,et al. Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine , 2008, Journal of psychopharmacology.
[22] A. Rush,et al. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder , 2008, Schizophrenia Research.
[23] L. Curtis,et al. Unit Costs of Health and Social Care 2016 , 2015 .
[24] K. Davidson. Cognitive Therapy for Personality Disorders: A Guide for Clinicians , 2007 .
[25] S. Rajagopal. The placebo effect , 2006 .
[26] P. Moran,et al. Personality disorders and unmet needs among psychiatric inpatients. , 2006, Psychiatric services.
[27] G. Dunn,et al. Reliability of the antipsychotic non-neurological side effects rating scale (ANNSERS) , 2005 .
[28] S. Wessely,et al. Active placebos versus antidepressants for depression. , 2004, The Cochrane database of systematic reviews.
[29] Steve Brown,et al. The psychiatric intensive care unit (PICU): Patient characteristics, treatment and outcome , 2004 .
[30] J. Hennen,et al. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. , 2003, Journal of personality disorders.
[31] B. Martindale. Borderline Personality Disorder: A Clinical Guide , 2002 .
[32] D. Black,et al. STEPPS: a cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder--a preliminary report. , 2002, Comprehensive psychiatry.
[33] T. McGlashan,et al. Treatment utilization by patients with personality disorders. , 2001, The American journal of psychiatry.
[34] S. Thompson,et al. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. , 2000, Statistics in medicine.
[35] M. First,et al. Structured clinical interview for DSM-IV axis II personality disorders : SCID-II , 1997 .
[36] H. Freeman,et al. Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland , 1996, British Journal of Psychiatry.
[37] P. Bebbington,et al. Psychosis Screening Questionnaire , 2014 .
[38] S. Fisher,et al. Suspended judgment. Seeing through the double-masked design: a commentary. , 1994, Controlled clinical trials.
[39] F. Frankenburg,et al. Clozapine treatment of borderline patients: a preliminary study. , 1993, Comprehensive psychiatry.
[40] Philip D. Harvey,et al. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. , 1991, The Journal of neuropsychiatry and clinical neurosciences.
[41] E. Ronningstam,et al. Early Discontinuance of Borderline Patients from Psychotherapy , 1989, The Journal of nervous and mental disease.
[42] J. Overall. The brief psychiatric rating scale (BPRS) : Recent developments in ascertainment and scaling. Introduction , 1988 .
[43] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.